Abstract
A retrospective study was conducted to evaluate the efficacy of levofloxacin in the treatment of Stenotrophomonas maltophilia bacteremia. The 30-day mortality rates were similar between the trimerthoprim-sulfamethoxazole (TMP-SMX) and levofloxacin treatment groups. Adverse events related to antibiotics occurred more frequently in patients receiving TMP-SMX, and recurrent bacteremia due to levofloxacin-resistant S. maltophilia strains developed in patients treated with levofloxacin. Our data suggest that levofloxacin can be a useful alternative option for treating S. maltophilia infections.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Anti-Bacterial Agents / adverse effects
-
Anti-Bacterial Agents / therapeutic use*
-
Bacteremia / drug therapy
-
Female
-
Gram-Negative Bacterial Infections / drug therapy*
-
Humans
-
Levofloxacin / adverse effects
-
Levofloxacin / therapeutic use*
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Retrospective Studies
-
Stenotrophomonas maltophilia
-
Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects
-
Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use*
Substances
-
Anti-Bacterial Agents
-
Levofloxacin
-
Trimethoprim, Sulfamethoxazole Drug Combination
Supplementary concepts
-
Stenotrophomonas maltophilia bacteremia